Kantarjian et al53 assessed the efficacy and safety of dasatinib, as in contrast with imatinib, for the primary-line cure of CML-CP. Five hundred and nineteen individuals with recently diagnosed CML-CP ended up randomly assigned to acquire dasatinib in a dose of a hundred mg once every day (259 individuals) or https://edwardv752lqu5.wikicorrespondent.com/user